PROPANC
Propanc is a research and development company developing treatments for cancer and other chronic diseases. The company focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer.
PROPANC
Social Links:
Industry:
Biotechnology Developer Platform Health Care Health Diagnostics
Founded:
2008-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.propanc.com
Total Employee:
1+
Status:
Active
Contact:
+61 (0)3 9614 2795
Email Addresses:
[email protected]
Total Funding:
150 K USD
Technology used in webpage:
ReCAPTCHA
Similar Organizations
Knopp Biosciences
Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.
Quantum Immunologics
Quantum Immunologics is engaged in the research, development, and production of immunologic treatment systems for breast cancers.
Senhwa Biosciences
Senhwa is a drug development company creating innovative therapies for cancer and related diseases.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.propanc.com
- Host name: ec2-3-220-137-4.compute-1.amazonaws.com
- IP address: 3.220.137.4
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Propanc"
Propanc - Crunchbase Company Profile & Funding
Organization. Propanc . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Propanc is a …See details»
Investor Relations :: Propanc Biopharma, Inc. (PPCB)
Transfer Agent. Securities Transfer Corporation 2901 N. Dallas Parkway Suite 380 Plano, Texas 75093 T: 469-633-0101 F: 469-633-0088 www.stctransfer.comSee details»
Propanc Biopharma Enters into Research Collaboration Agreement …
MELBOURNE, Australia, Sept. 19, 2018 /PRNewswire/ -- Propanc Biopharma, Inc. (OTCQB: PPCB) ("Propanc Biopharma" or the "Company"), a clinical stage biopharmaceutical company …See details»
PROPANC HEALTH GROUP CORPORATION FORM 10-Q …
PROPANC HEALTH GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 33-0662986 (State or other jurisdiction of incorporation or organization) …See details»
Propanc Biopharma Receives Certificate of Grant for “Proenzymes ...
MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer …See details»
Propanc Biopharma Advances POP1 Joint Research and Drug …
MEDINA is a Non-Profit Research Organization established in 2008 through a public-private alliance between the Regional Government of Andalusia, Spain, the pharmaceutical company …See details»
Propanc Biopharma Initiates European Validation of its Lead Patent
MELBOURNE, Australia, Oct. 4, 2018 /PRNewswire/ -- Propanc Biopharma, Inc. (OTCQB: PPCB) ("Propanc Biopharma" or the "Company"), a clinical stage biopharmaceutical company …See details»
Washington, D.C. 20549 SECURITIES AND EXCHANGE …
PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 33-0662986 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) …See details»
CORRECTING and REPLACING Propanc Biopharma Publishes Key …
Aug 13, 2019 Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, …See details»
Propanc Biopharma’s CEO Believes Lead Asset Could ... - Business …
Jul 12, 2022 Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients. July 12, 2022 09:00 …See details»
Propanc Biopharma’s CEO Comments on the 39 Granted Patents …
MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer …See details»
Propanc Biopharma Changes Ticker Symbol to "PPCB"
According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global …See details»
Securities Purchase Agreement dated February 7, 2025 | Propanc ...
Feb 7, 2025 This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 7, 2025, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, …See details»
Propanc Biopharma Advances POP1 Joint Research and Drug …
Dec 31, 2020 MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer …See details»
Propanc Biopharma Receives Certificate of Grant for "Composition …
Apr 16, 2024 Propanc Biopharma, Inc. (the "Company") is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target …See details»
Propanc Biopharma Announces Joint Research Partnership with …
MELBOURNE, AUSTRALIA -- (Marketwired) -- 07/18/17 -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company …See details»
Propanc Biopharma Receives Notice of Allowance for Method to …
Mar 22, 2022 MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer …See details»
PPCB Message Board | Propanc Biopharma Inc - Market Wire News
PPCB - Propanc Biopharma's CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors British Journal of Cancer …See details»
Propanc Biopharma Receives Allowance of Key Patent Application …
According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global …See details»